Isolated iris involvement as the presenting feature of recurrence in primary testicular diffuse large B-cell lymphoma: a case report and literature review

The clinical manifestations of iris lymphoma are nonspecific and can easily be confused with other ophthalmic diseases, leading to misdiagnosis. This study reports a case of primary testicular diffuse large B-cell lymphoma in a patient who developed isolated iris recurrence after achieving complete remission. Following treatment with a targeted combination regimen consisting of Zanubrutinib, Obinutuzumab, and Polatuzumab vedotin, the patient's disease remained stable, with a follow-up duration of 22 months from treatment initiation to the last follow-up. Relevant literature is reviewed to summarize the clinical characteristics and treatment strategies for iris lymphoma, aiming to enhance clinicians' awareness of this rare pattern of ocular recurrence and provide insights for its management.

Authors

Institutions

Publication Details

Journal
Journal of Medical Case Reports
Published
2026-11-16
DOI
https://doi.org/10.1186/s13256-026-06857-4
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Isolated iris involvement as the presenting feature of recurrence in primary testicular diffuse large B-cell lymphoma: a case report and literature review

沈卫章, Meng Gao, Meng Zhao
2 links
Journal of Medical Case Reports
Lymphoma Diagnosis and Treatment
article

Isolated iris involvement as the presenting feature of recurrence in primary testicular diffuse large B-cell lymphoma: a case report and literature review

沈卫章, Meng Gao, Meng Zhao
article en

Abstract

The clinical manifestations of iris lymphoma are nonspecific and can easily be confused with other ophthalmic diseases, leading to misdiagnosis. This study reports a case of primary testicular diffuse large B-cell lymphoma in a patient who developed isolated iris recurrence after achieving complete remission. Following treatment with a targeted combination regimen consisting of Zanubrutinib, Obinutuzumab, and Polatuzumab vedotin, the patient's disease remained stable, with a follow-up duration of 22 months from treatment initiation to the last follow-up. Relevant literature is reviewed to summarize the clinical characteristics and treatment strategies for iris lymphoma, aiming to enhance clinicians' awareness of this rare pattern of ocular recurrence and provide insights for its management.

Journal of Medical Case Reports
Jilin University (CN), Second Affiliated Hospital of Jilin University (CN)
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon